The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Multiple Sclerosis Follow-Up

Multiple sclerosis (MS) follow-up — interferon, glatiramer, oral DMTs and B-cell therapies in RRMS.

Outpatient follow-up of disease-modifying therapies (DMTs) used to reduce relapses and slow disability progression in MS, a demyelinating disease of the central nervous system.

Indication

  • Diagnosis or suspicion of relapsing-remitting MS (RRMS)
  • Secondary progressive (SPMS) and primary progressive (PPMS) MS
  • Follow-up of clinically isolated syndrome (CIS)
  • New demyelinating lesions on MRI
  • Relapse (flare) management and steroid therapy
  • DMT selection, monitoring of effectiveness, and side-effect surveillance

Preparation

  • Bring previous MRI and cerebrospinal fluid (CSF) reports to the visit
  • Note the current DMT, dose, and any side effects experienced
  • Review of vaccination status (especially before B-cell therapy)
  • Inform the physician of any pregnancy plans

How it's performed

  1. Neurological examination and EDSS (disability) scoring
  2. Brain and cervical-thoracic spinal cord MRI
  3. Lumbar puncture for oligoclonal bands when indicated
  4. First-line DMT: interferon-beta or glatiramer acetate
  5. Oral DMT options: fingolimod, dimethyl fumarate, teriflunomide
  6. B-cell-depleting therapy in highly active MS: ocrelizumab

Post-procedure

  • Visits every 3-6 months in the first year, then every 6-12 months
  • Annual MRI to monitor new lesions and atrophy
  • Complete blood count, liver function, and thyroid function tests
  • Management of fatigue, bladder, mood, and cognitive symptoms
  • Referral to physiotherapy and occupational therapy

Risks

  • Interferon: injection-site reactions, flu-like side effects
  • Fingolimod: first-dose bradycardia, macular edema
  • Dimethyl fumarate: facial flushing, lymphopenia
  • Ocrelizumab: infusion reactions, increased infection risk (especially respiratory)
  • JC virus-associated PML (especially with natalizumab; rare)

FAQ

Is MS hereditary?

MS is not directly hereditary; however, the risk is slightly higher than in the general population if a family member has MS.

Which DMT is best?

The optimal therapy is individualized based on disease activity, MRI findings, side-effect profile, and pregnancy plans.

How is a relapse (flare) treated?

High-dose intravenous methylprednisolone is typically given for 3-5 days. Plasma exchange may be considered if there is no response.

Is pregnancy possible with MS?

It is possible for most patients; the DMT should be reviewed before conception, and planning should be done together with the physician.

Related Information